- Conditions
- Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
- Interventions
- Leukapheresis, Fludarabine, Cyclophosphamide, CD33-CAR-T Cell Infusion
- Procedure · Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 29,129
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anthrax
- Interventions
- AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
- Biological
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
- Conditions
- Pharmacokinetics
- Interventions
- Voriconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Durham, North Carolina + 5 more
- Conditions
- Cystic Fibrosis, Prediabetes
- Interventions
- Sitagliptin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Columbus, Ohio
- Conditions
- Asthma
- Interventions
- Tozorakimab, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 65
- States / cities
- Bakersfield, California • Huntington Beach, California • La Mesa, California + 61 more
- Conditions
- Myasthenia Gravis
- Interventions
- Nipocalimab, Efgartigimod
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 20
- States / cities
- Fullerton, California • Pomona, California • Colorado Springs, Colorado + 17 more
- Conditions
- Lymphoma
- Interventions
- lenalidomide
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 3
- States / cities
- Stanford, California • Chicago, Illinois • Houston, Texas
- Conditions
- Hodgkin Lymphoma
- Interventions
- doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 9
- States / cities
- Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, Levomilnacipran, Fluoxetine
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 48
- States / cities
- Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more
- Conditions
- Thrombocytopaenia
- Interventions
- Eltrombopag, Boceprevir, Telaprevir
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 1 Diabetes
- Interventions
- Tandem Automated Insulin Delivery System
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 2 Years to 26 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
- Interventions
- Sym004, Futuximab, Modotuximab
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Neoplasms
- Interventions
- BAY1143572
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Fayetteville, Arkansas • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
- Conditions
- Gastric Cancer, Stomach Cancer
- Interventions
- Potentially curative surgery, Floxuridine (IP), Adjuvant Chemoradiation therapy
- Procedure · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Human Insulin Inhalation Powder, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 24
- States / cities
- Fresno, California • Pomona, California • West Palm Beach, Florida + 21 more
- Conditions
- Asthma
- Interventions
- AIR645, Physiologic saline solution
- Drug
- Lead sponsor
- Altair Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
- Interventions
- MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing
- Biological · Drug · Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neoplasms
- Interventions
- GSK3174998, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Alcohol Dependence
- Interventions
- RDC-0313, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- AZD4877
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Houston, Texas • San Antonio, Texas
- Conditions
- Neonatal Apnea, Infants
- Interventions
- Caffeine Citrate
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 0 Days to 27 Weeks
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Multiple Myeloma, Patient Participation
- Interventions
- Doxil, melphalan, bortezomib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- RSV Infection, QTc Interval
- Interventions
- zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • San Antonio, Texas